Galmed Phar stock hits 52-week low at $2.21 amid challenges

Published 26/02/2025, 16:34
Galmed Phar stock hits 52-week low at $2.21 amid challenges

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) stock has reached a 52-week low, touching down at $2.21, representing a stark 90% decline from its 52-week high of $23.80. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 7.03, though its market capitalization has contracted to just $3.75 million. This low point reflects a significant downturn from previous valuations, with the stock experiencing a substantial decline of 41% over the past year. While InvestingPro analysis suggests the stock is currently undervalued, investors are closely monitoring Galmed’s strategic moves and potential catalysts that may influence recovery. The company maintains a solid balance sheet with more cash than debt, though profitability remains a key concern according to InvestingPro metrics (6 additional InvestingPro Tips available).

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.